Intermittent versus continuous androgen deprivation therapy to biochemical recurrence after external beam radiotherapy: a phase 3 GICOR study

Abstract

No significant differences were seen in DP and QLQ between intermittent (6 months) and continuous (36 months) ADT in patients with BF after EBRT.

Intermittent androgen deprivation therapy: recommendations to improve the management of patients with prostate cancer following the GRADE approach

“…We reviewed 18 full texts and excluded 15 references ( Supplementary materials ). We included information from three new trials in addition to those identified by Magnan et al 22 – 24 The justified reference list of included and excluded studies is presented in Supplementary materials .…”

“…Furthermore, we identified three additional trials published from 2014 to 2017. 22 – 24 These additional studies included from 74 to 701 patients; the median age of patients ranged from 72 to 74 years. One study focused on locally advanced PCA patients.…”

“… 21 An additional trial published in 2016 did not find statistically significant differences between CADT and IADT groups in patients with relapsing M0 or locally advanced PCA (43 versus 41 events; P =0.865). 22 Another trial published in 2017 reported the number of patients with disease progression (defined as PSA ≥4 ng/mL and/or metastases); 24 the authors found three patients with disease progression in the intermittent group versus zero patients in the continuous arm after follow-up, but they concluded that there were no significant differences between assessed groups related to this outcome. 24 Quality of evidence was downgraded from high to moderate due to issues related to the risk of bias ( Table 1 ).…”

Intermittent androgen deprivation therapy in patients with prostate cancer: Connecting the dots

“…Retrospective and single arm studies were not included. Besides these seven studies, there were few other studies comparing IADT and CADT for which we have listed the methods/results in Table 2 [16] , [26] , [27] , [28] , [29] , [30] , [31] , [32] , [33] , [34] .…”

“…Cognitive function significantly reduced in IADT 87% to baseline, 69% (p < 0.05) CADT 127 CPA 100 mg 3 times daily Casas. 2016 [32] Patients with biochemical failure after external beam radical radiotherapy Non-inferiority, randomized, phase 3 IADT 38 IADT (6 months) and CADT (36 months) NR NR 48 (median) NR No patient with risk of progression 3 with risk of progression NR NR No significant differences in QoL score between groups CADT 39 Schulman. 2016 [33] Non-metastatic relapsing or locally advanced Phase 3, open-label, randomized IADT 340 6 months induction with leuprorelin acetate 22.5 mg 3-month depot; Patients were randomized with leuprorelin for 36 months ≤1 ≥2.5 18 Time to PSA progression Time to PSA progression: p = 0.718 NS Estimated 3 years PSA progression comparable between IADT (10.1%) and CADT (10.6%); NS NR 42 deaths QoL comparable between groups; Hot flushes, hypertension, constipation CADT 361 44 deaths p = 0.969; NS Tsai.…”